John P. Sharp - 24 Feb 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 24 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2022, 18:30:49 UTC
Prior SEC filing: 23 Nov 2021
Next SEC filing: 24 May 2022
Source filing: View source filing
Reporting owner signature: /s/ John P. Sharp

Key filing fact

John P. Sharp filed Form 4 for PhaseBio Pharmaceuticals Inc on 28 Feb 2022.

Key facts

This page summarizes John P. Sharp's Form 4 filing for PhaseBio Pharmaceuticals Inc.
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Feb 2022, 18:30.

Change

Previous filing in this sequence was filed on 23 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PHASQ transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +24,750
Change %
Price: $0.000000
Shares after: 24,750
Date: 24 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,750
Exercise price
Footnotes: F1, F2

PHASQ transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +115,500
Change %
Price: $0.000000
Shares after: 115,500
Date: 24 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 115,500
Exercise price: $1.13
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit is the economic equivalent of one share of PhaseBio Pharmaceuticals, Inc. common stock and is converted into common stock upon vesting subject to the reporting person's continued service through each such date.

Footnote F2

These Restricted Stock Units vest in equal one-third amounts on April 1, 2023, 2024, and 2025.

Footnote F3

The shares subject to the option shall vest in equal monthly installments over 48 months from February 24, 2022, subject to the reporting person's continued service through each such date.